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Abstract
The ficolins are soluble pattern recognition molecules in the lectin pathway of complement, but the spectrum and mode of
interaction with pathogens are largely unknown. In this study, we investigated the binding properties of the murine serum
ficolin-A towards a panel of different clinical relevant microorganisms (N=45) and compared the binding profile with
human serum ficolin-2 and ficolin-3. Ficolin-A was able to bind Gram-positive bacteria strains including E. faecalis,
L. monocytogenes and some S. aureus strains, but not to the investigated S. agalactiae (Group B streptococcus) strains.
Regarding Gram-negative bacteria ficolin-A was able to bind to some E. coli and P. aeruginosa strains, but not to the
investigated Salmonella strains. Of particular interest ficolin-A bound strongly to the pathogenic E. coli, O157:H7 and O149
strains, but it did not bind to the non-pathogenic E. coli, ATCC 25922 strain. Additionally, ficolin-A was able to bind purified
LPS from these pathogenic strains. Furthermore, ficolin-A bound to a clinical isolate of the fungus A. fumigatus. In general
ficolin-2 showed similar selective binding spectrum towards pathogenic microorganisms as observed for ficolin-A indicating
specific pathophysiological roles of these molecules in host defence. In contrast, ficolin-3 did not bind to any of the
investigated microorganisms and the anti-microbial role of ficolin-3 still remains elusive.
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Introduction
The ficolins are recognition molecules in the lectin pathway of
the complement system that bind to specific structures on
microorganisms and self cellular debris enabling quick and simple
aggregation and opsonization of hazardous material [1,2].
The ficolins are highly oligomerized glycoproteins containing
both collagen-like (CL) and fibrinogen-like (FBG) regions. As seen
for mannose-binding lectin (MBL), the CL region is able to
associate with the MBL/ficolin associated serine proteases
(MASPs), which activate the lectin pathway of the complement
system [1]. The ficolins are built up of several structural subunits
each composed of three identical polypeptide chains [3–5].
Through the FBG domain they bind structures such as N-acetyl-
glucosamine (GlcNAc), N-acetyl-galactosamine (GalNAc), and
acetylated compounds located on the target cell [6,7].
The ficolins have been described in both vertebrates and
invertebrates where each species contain several paralogues
ficolins (typical 2–4). In human, three ficolins are described:
ficolin-1 (M-ficolin), ficolin-2 (L-ficolin), and ficolin-3 (H-ficolin).
Ficolin-1 is present in low serum concentrations whereas ficolin-2
and ficolin-3 are present in concentrations of ,5 mg/ml and
,25 mg/ml, respectively [8–11]. Two ficolin molecules have been
identified in mice termed ficolin-A and ficolin-B. Ficolin-B is
expressed in myeloid bone marrow derived cells and ficolin-A is
expressed in the liver and spleen and is present in serum [5,12].
Based on the protein sequence and exon organisation it is likely
that ficolin-B is the orthologue to the human ficolin-1, whereas
both the mouse ficolin-A and the human ficolin-2 seems to have
evolved independently from a common ficolin-1/ficolin-B lineage
[13,14]. The mouse homologue of the human ficolin-3 gene is
identified as a pseudogene in mice and rats [15].
Both ficolin-1 and ficolin-2 have been shown to bind different
bacteria strains such as Staphylococcus aureus, Salmonella typhimurium,
Streptococcus pneumonia, Streptococcus pyogenes and Streptococcus agalactiae
and are able to stimulate phagocytosis by polymorphonuclear
neutrohpils and monocytes [16–18]. However, the anti-bacterial
significance of ficolin-3 still remains to be determined.
In this study we investigated the binding of the murine serum
ficolin-A towards a panel of different clinical relevant bacterial and
fungal strains and compared this binding profile with that from
human serum ficolin-2 and ficolin-3.
Results
Ficolin Quantification Assay
Since no commercial antibodies against ficolin-A are currently
available for a quantification assay we optimized an ELISA setup
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molecule. Recombinant ficolin-A, ficolin-2 and ficolin-3 were able
to bind acBSA in a dose dependent manner and this assay was
used for determination of ficolin binding to microorganisms.
Binding of Ficolins to Microorganisms
The binding of mouse ficolin-A and human ficolin-2 and ficolin-
3 were investigated towards a panel of different microorganisms
(table 1). Binding was detected by incubating bacteria or fungus
with ficolins and the residual ficolin protein in the supernatant
after centrifugation was measured and the percentage of
remaining ficolin was determined. A result of 100% indicates no
binding to microorganisms whereas 0% indicates complete
binding. Values between 100% and 75% were not considered as
positive interaction between ficolins and microorganisms. Positive
binding was determined to be percentage value below 75% and
values below 10% were considered as very strong binding. Ficolin-
A and ficolin-2 were able to bind several of the investigated
microorganisms (Fig.1A and Fig.1B). Ficolin-A interacted with all
the Enterococcus faecalis (EFs) strains and bound strongly to all the
Listeria monocytogenes (LMs) strains (Fig.1A). It also binds to
Staphylococcus epidermidis (SE) and Aspergillus fumigatus (AF). Ficolin-
A selectively interacts with some strains of Escherichia coli (ECs) and
Pseudomonas aeruginosa (PSs). Ficolin-2 interacted with all E. faecalis
(EFs) strains as wells as the S. epidermidis (SE) and A. fumigatus (AF).
As ficolin-A, ficolin-2 bound selectively to some E. coli (ECs) and
P. aeruginosa (PSs) strains (Fig.1B) and to some degree to the
Salmonella (ST, SD, SG) strains. At these settings, ficolin-3 did not
interact with any of the bacteria strains investigated (Fig.1C).
Control experiments demonstrated ficolin-3 binding to acBSA-
coupled sepharose beads and not to BSA coupled sepharose beads.
A serial dilution of the bacteria was incubated with fixed
concentrations of the ficolins. A dose-dependent ficolin-A binding
was confirmed to E. faecalis (EF2), L. monocytogenes (LM2), E. coli
(EC2), P. aeruginosa (PS2) and A.fumigutus (AF) (Fig.2A). Binding of
ficolin-2 was also confirmed to E. faecalis (EF2), A. fumigatus (AF),
E. coli (EC2) and P. aeruginosa (PS2) although the dose-dependency
was not as dynamic as seen for ficolin-A (Fig.2B). No binding to
bacteria was detected for ficolin-3 (Fig.2C).
Ficolin-A was incubated with relevant microorganisms and the
bacteria cells were analysed on SDS-PAGE followed by western
blotting (Fig.3A). Ficolin-A binding was confirmed to E. faecalis
(EF2), L. monocytogenes (LM2), E. coli (EC2) and P. aeruginosa (PS2).
Weaker binding was detected to E. coli (EC3) and P. aeruginosa
(PS1). No binding was detected to S. Typhimurium (ST). Control
experiments showed no binding to mannan-agarose beads but
positive binding to GlcNAc-agarose beads. These data were
supported by analyzing the supernatant containing the unbound
protein on an acBSA matrix (Fig.3B).
Binding of Serum Ficolin-A to Microorganisms
Bacteria were incubated with ficolin-A knock-out serum or
wildtype serum. Ficolin-A binding was detected in the wildtype
serum to A. fumigatus (AF), E. coli (EC2), P. aeruginosa (PS2), E.
faecalis (EF2) and L. monocytogenes (LM2) (Fig.4). These data confirm
the results obtained with recombinant ficolin-A.
Binding of Ficolin-A to LPS
Overnight bacteria culture was cleared from bacteria cells by
centrifugation and the medium was sterile filtrated and incubated
in different dilutions with ficolin-A and added to acBSA plates.
The ficolin-A binding to the acBSA matrix was inhibited with
increased concentration of bacteria growth medium from L. mono-
cytogenes (LM2), E. faecalis (EF2), E. coli (EC2) and P. aeruginosa (PS2)
(Fig.5A). However, no inhibition to acBSA was observed when
incubating ficolin-A with growth medium from S. aureus (SA19), S.
Typhimurium (ST) or P. aeruginosa (PS1). In order to investigate if the
bacteria produce proteases that inactivate ficolin-A, and thereby
could explain the observed reduced binding to acBSA, the bacteria
overnight culture medium was heat inactivated, sterile filtrated
and incubated with ficolin-A and measured on the acBSA plates
(Fig.5B). No difference between the heat-inactivated growth
Table 1. investigated microorganisms and ligands.
ABBAbbrev. Name Gram-classification N
SA Staphylococcus aureus Positive 19
SR Streptococcus agalactiae (Group B) Positive 6
EF Enterococcus faecalis Positive 6
LM Listeria monocytogenes Positive 3
SE Staphylococcus epidermidis Positive 1
ST Salmonella Typhimurium Negative 1
SD Salmonella Dublin Negative 1
SG Salmonella Gallinarium Negative 1
EC Escherichia coli Negative 3
PS Pseudomonas aeruginosa Negative 2
KB Klebsiella pneumoniae Negative 1
AF Aspergillus fumigatus Negative 1
acBSA-B acetylated bovine serum albumin sepharose beads – –
BSA-B bolive serum albumin sepharose beads – –
PBS phosphate buffered saline – –
Mannose-B mannose agarose beads – –
GlcNAc-B N-acetyl-D-glycosamine agarose beads – –
doi:10.1371/journal.pone.0038196.t001
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indicate that the ficolin-A binding bacteria strains excrete
substances such as LTA or LPS to the culture medium that
inhibits the binding of ficolin-A to acBSA. LPS was purified from
the investigated Gram-negative bacteria and coated on a poly-
styrene plate and ficolin-A was added in a serial dilution and the
binding was detected. Ficolin-A bound LPS from E. coli (EC2) and
to some degree to LPS from P. aeruginosa (PS2) (Fig5C).
Binding of Ficolin-A to A. Fumigatus Using Flow
Cytometry
Flow cytometry was used to examine the binding of ficolin-A to
A. fumigatus. The microorganism was incubated with recombinant
ficolin-A and detected with polyclonal rabbit anti-mouse ficolin-A
(Japan) antibody followed by FITC-conjugated anti-rabbit IgG.
Fig.6A shows a significant dose-dependent binding of ficolin-A to
A. fumigatus. This binding was inhibited by GlnNAc but not
mannose (Fig.6B).
Binding of Ficolin-A to Microorganisms Using Confocal
Laser Scanning Microscope (CLSM)
Interaction between ficolin-A and different microorganisms were
assessed by CLSM. Ficolin-A bound strongly to all of the conidia
cells of A. fumigatus (Fig.7A). No fluorescence was observed when
incubating without ficolin-A (Fig.7B) or with ficolin-3 with
respective antibodies (data not shown). The binding of ficolin-A
to A. fumigatus was inhibited with GlcNAc but not EDTA or
mannose (Fig.7C).
Ficolin-A binding was detected to E. coli (EC2), however this
interaction was restricted to aggregated cells only (Fig.8A). All
aggregated bacteria on the slide were positive. No binding of
aggregated E. coli (EC3) was detected (Fig.8B). As expected based
on the previous results, no binding was detected to S. Typhimurium
(ST) (data not shown).
Ficolin-A also bound aggregates of E. faecalis (EF2) but not single
cells (Fig.9A). No signal was detected when incubating without
ficolin-A (Fig.9B). The binding appeared to be concentrated to
large aggregates (Fig.9C).
Discussion
The innate immune system consists of various types of cells and
molecules that specifically interact with each other to initiate
a quick and effective host defence. The murine ficolin-A and
human ficolin-2 and ficolin-3 are serum proteins that bind to
carbohydrate structures and acetylated compounds displayed on
the surfaces of both mammalian tissues and on microorganisms
[19–21]. Carbohydrates may be arranged into extremely variable
structures, which on some microorganisms allow the ficolins to
Figure 1. Binding of the ficolins to different microorganisms. After incubation of the microorganisms (1610
8 cells) with 0.2 mg of either
recombinant ficolin-A (A), ficolin-2 (B) or ficolin-3 (C) the concentration of residual ficolin was estimated on acBSA coated polystyrene plates. Binding
is indicated with decreased percentage signals related to PBS where 75–100% reflects no binding. Strong interaction between the ficolins and
microorganisms is indicated with values below 10%. OD450nm values at 100% for the ficolin-A, ficolin-2 and ficolin-3 assays were 2.039, 0.920 and
1.641, respectively. Error bars indicate standard derivations of duplications. The experiment was repeated three times showing similar data.
doi:10.1371/journal.pone.0038196.g001
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have been shown to be involved in activities such as opsonization,
activation of complement and phagocytosis [2,4]. In this study we
investigated the binding of the mouse ficolin-A to a number of
different clinical relevant microbial strains and compared this
binding profile to human serum ficolin-2 and ficolin-3.
The results of this work demonstrate a broad binding profile of
mouse ficolin-A towards both Gram-positive and Gram-negative
bacterial strains. Significant ficolin-A binding was detected
towards all the investigated E. faecalis and L. monocytogenes strains
whereas only some of the E. coli strains and P. aeruginosa strains
reacted with ficolin-A. Ficolin-A also showed a strong binding
towards S. epidermidis and the fungus A. fumigatus. A similar binding
profile was observed for human ficolin-2. However, this molecule
also binds to Salmonella strains to some degree. In contrast, ficolin-2
did not bind L. monocytogenes in the same degree as ficolin-A.
Ficolin-2 has previously been shown to bind to Gram-positive
bacteria such as S. pneumoniae, S. agalactiae and S. aureus, and to
Gram-negative bacteria such as S. typhimurium and E. coli [20,22].
In this study we detected binding of ficolin-2 to only a few strains
of S.aureus and the binding was apparently weaker to these strains
compared to strains such as E. faecalis or some strains of E. coli.I t
has been shown that ficolin-2 only bind to capsulated S. aureus
strains and not to noncapsulated strains [22]. Many bacteria,
including both Gram-positive and Gram-negative, may be covered
by an outer polysaccharide-containing layer termed the capsule
layer. In the case of human pathogens, a large number of different
capsule serotypes have been identified. For example, over 80
different capsular polysaccharides or K antigens have been
described for E. coli [23,24]. Various functions have been
attributed to capsules including protection from desiccation [25]
and adherence to surfaces and other bacteria contributing to
biofilm formation [23]. Capsules often play a role in pathogenicity
[26] acting as virulence factors to protect cells from phagocytosis
and complement-mediated killing. The synthesis of the capsular
material depends upon the environment and whether the bacteria
cultures are able shift their morphology during growth. The
bacteria used in this work were grown exponential overnight in LB
medium and contains likely a mixture of both capsulated and
noncapsulated strains. Investigating a S. aureus bacteria culture that
has been optimized for production of capsules may show a stronger
interaction as described by Krarup et al. [22]. The same issue may
be relevant for other bacteria strains as the Group B Streptococci that
previously has been shown to bind ficolin-2 [16], where we could
only confirm a weaker binding to these strains. However, it may be
difficult to compare ‘‘strength’’ of ficolin binding to bacteria with
previous published papers since the assays have been performed
with different setting. Previous reports have demonstrated ficolin-3
does not appear to have a broad binding specificity towards
pathogens [27]. The only bacteria that have been shown to
interact with ficolin-3 are Aerococcus viridians and Hafnia alvei [27,28]
and the anti-microbial binding profile of the human ficolins is
thereby very different. Supporting these data, the carbohydrate
binding specificity of the human ficolins has been analyzed by
glycan array screening demonstrating that ficolin-2 bind several
different carbohydrates such as disulfated N-acetyllactosamine and
tri- and tetra-saccharides containing terminal galactose or GlcNAc
whereas ficolin-3 shows a very poor lectin activity [29]. Recently
a mutation in the FCN3 gene causing ficolin-3 deficiency has been
observed in a patient with recurrent severe infections of different
aetiologies [10] and ficolin-3 has also been shown to be important
in tissue homeostasis [2,30]. Thus it is at present unresolved
whether ficolin-3 deficiency is directly associated with increased
risk of infections or may aggravate the consequences of tissue
damage caused by infections.
The group of E. faecalis bacteria appears to be a specific target
for both ficolin-A and ficolin-2. E. faecalis is a opportunistic Gram-
positive cocci that normally inhabits the intestinal tract but it may
Figure 2. Dose-dependent binding of the ficolins (0.2 mg) to
microorganisms. Ficolin-A showed strong binding to E. faecalis (EF2),
A. fumigatus (AF), L. monocytogenes (LM1), E. coli (EC2) and P. aeruginosa
(PS2) (A). Ficolin-2 showed binding to all six microorganisms (B). Ficolin-
3 did not bind any of the bacteria but a weak binding was observed to
A. fumigatus (AF) (C). GlcNAc-agarose beads and acBSA-coated
sepharose beads were included as positive controls. Binding is
indicated with decreased percentage signals related to PBS where
100% reflects no binding. OD450nm values at 100% for the ficolin-A,
ficolin-2 and ficolin-3 assays were 1.263, 2.561 and 1.338, respectively.
Error bars indicate standard derivations of duplicates. The results shown
are typical of three experiments.
doi:10.1371/journal.pone.0038196.g002
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infections (for review see [31]). Ficolin-A and ficolin-2 also bind to
different small-colony variants (SCVs) (EF4, EF5, EF6) in a similar
manner as the normal E. faecalis counterpart (EF3). SCVs
constitute slow-growing subpopulations of the bacteria with
distinct phenotypes having more pathogenic characteristics. It
might be speculated that mouse ficolin-A and human ficolin-2
have an important function in controlling this pathogen.
Furthermore, the binding was only detected to large aggregates
of this bacteria and whether the interaction is directly to the
bacteria cell wall or to biofilm remains to be investigated.
The binding of the serum ficolins was investigated towards three
different E. coli strains; O149 (EC1), O157:H7 (EC2) and
ATCC25922 (EC3). Both ficolin-A and ficolin-2 bind to the
pathogenic E. coli strains O149 and O157:H7 but not the non-
pathogenic E. coli ATCC25922. Supporting these data, ficolin-2
has recently been shown to bind the E. coli O104:H4 that were
responsible for the recent outbreak of food poisoning in Germany
causing haemolytic-uremic syndrome (HUS) [32].
The bacterium O157:H7 has been implicated in several
outbreaks of hemorrhagic colitis included fatalities caused by
haemolytic uraemic syndrome [33,34] and the E. coli O149 is
a pathogen that may lead to porcine postweaning diarrhea causing
major problems in the pig industry worldwide [35]. The binding of
ficolin-A to E. coli O157:H7 (EC2) was only detected to aggregated
cells and not to single cells. E. coli strains are able to produce
biofilm and the binding mechanism may be the same as observed
for E. faecalis. Sterile filtrated overnight growth medium from the
bacteria that associate with ficolin-A was able to inhibit the
binding of ficolin-A to acBSA in a similar pattern as observed
when using living bacteria. Therefore, we speculated whether the
bacteria were able to produce enzymes that could inactivate the
ficolin molecules. However, 96uC heat-inactivated bacteria growth
medium showed a similar binding profile as observed with
unheated growth medium. This strongly suggests that the reduced
Figure 3. Binding of the ficolin-A to microorganisms. After incubation of the bacteria with recombinant ficolin-A the bacteria were washed
three times and analysed on SDS-PAGE followed by western blotting (A). Binding was detected to GlcNAc-agaose beads (GlcNAc-B) but not mannose-
agarose beads (Mannose-B). Strong binding was observed to A. fumigatus (AF), E. coli (EC2), P. aeruginosa (PS2), E. faecalis (EF2) and L. monocytogenes
(LM1). Residual concentration of ficolin-A in the supernatant was analysed on acBSA-coated polystyrene plates (B). Binding is indicated by low
percentage value where 100% reflects no binding. OD450nm value at 100% was 1.799. Error bars indicate standard derivations of two experiments.
doi:10.1371/journal.pone.0038196.g003
Figure 4. Binding of serum ficolin-A to microorganisms. Ficolin-A knock-out serum and wild type serum was incubated with different
microorganisms. After incubation of the bacteria (1610
8 cells) with serum diluted 1:50 in Barb-T buffer, the concentration of residual ficolin-A was
estimated on acBSA coated polystyrene plates. Binding is indicated with decreased percentage signals where 100% reflects no binding. Binding was
detected to A. fumigatus (AF), E. coli (EC2), P. aeruginosa (PS2), E. faecalis (EF2) and L. monocytogenes (LM1). OD450nm at 100% is 2.731. Error bars
indicate standard deviations of duplicates.
doi:10.1371/journal.pone.0038196.g004
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digestion of ficolin-A but rather an affinity inhibition of the
detection assay by secreted structures such as LPS or LTA.
Ficolin-2 has been shown to bind LTA from S. aureus, S. pyogenes
and S. agalactieae and thereby initiate the lectin pathway-dependent
C4 turnover [20]. Furthermore, porcine ficolin-a react with LPS
from different bacteria such as E. coli, S. typhimurium, S. enteritidis
and P. aeruginosa and LTA from the S. pyogenes and S. aureus [18].
In order to study the binding of ficolin-A to endotoxins, we
purified LPS from the investigated Gram-negative bacteria and
measured the binding of LPS to ficolin-A. Ficolin-A was able to
bind to LPS from the pathogenic E. coli O157:H7 (EC2) but not
the non-pathogenic E. coli ATCC25922 (EC3). It might be
speculated that LPS is the ligand structure for ficolin-A upon
immune recognition of the pathogen. However, the binding of
ficolins to released LPS from the pathogenic E. coli O157:H7
(EC2) could also be an evasion mechanism of the bacteria to
hamper recognition and sequestration by innate immunity
mechanisms as complement deposition, opsonization and phago-
cytosis.
We demonstrated a clear binding of ficolin-A towards
A. fumigatus. We have previously shown that ficolin-2 binds to
certain A. fumigatus strains [36] and this interaction was confirmed
with new isolates in the present study. The binding of ficolin-A to
A. fumigatus seems to be located to the cell membrane of the conidia
and the binding was inhibited by GlcNAc but not mannose
Figure 5. Binding of ficolin-A to bacterial components. The
binding of ficolin-A (0.2 mg) to acBSA was inhibited with sterile filtrated
overnight bacterial growth medium from some of the bacteria (A). No
differences were observed when the growth medium was heat
inactivated at 96uC (B). Purified LPS was coated on polystyrene plates
and serum from ficolin-B knock-out serum diluted 1:10 in Barb-T buffer
was added (C). Ficolin-A binding to LPS from E. coli (EC2) was detected
in a dose-dependent manner. Error bars indicate standard deviations of
duplicates. Shown is one representative experiment of three.
doi:10.1371/journal.pone.0038196.g005
Figure 6. Binding of ficolin-A to A. fumigatus conidia using flow
cytometry. A. fumigatus (1.4610
6 cells) were incubated with elevated
concentration of ficolin-A (A). Bound protein was detected with
polyclonal rabbit anti-mouse ficolin-A antibody. A. fumigatus (1.4610
6
cells) were incubated with ficolin-A (30 mg/ml) in the presence of
GlcNAc or mannose, respectively (B). Bound ficolin-A was detected as
depicted above. As a control, A. fumigatus was incubated in the
absence of ficolin-A. Results are representative of three independent
experiments that yield similar results.
doi:10.1371/journal.pone.0038196.g006
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These data may indicate that the contact between ficolin-A and
the fungus is a result of a direct immune mechanism for tagging
the microorganism for phagocytosis and complement deposition.
The long pentraxin PTX3 has been shown to bind to A. fumigatus
and to be critical against infection in mice models [37,38]. We
have previously demonstrated that ficolin-2 interacts with PTX3
[36] and that these two proteins might work synergistically against
A. fumigatus in vitro. A. fumigatus has become one of the most
Figure 7. Binding of ficolin-A to A. fumigatus using confocal laser scanning fluorescence microscopy. A. fumigatus (4610
6 cells) was
incubated with ficolin-A (5 mg/ml) (A) or without ficolin-A (B). The binding was inhibited with GlcNAc but not EDTA or mannose (C). The binding was
detected with a monoclonal rat anti-mouse ficolin-A antibody.
doi:10.1371/journal.pone.0038196.g007
Ficolin-A and Microorganisms
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fatal invasive infections in immunocompromised patients [39].
Even though ficolin-A and ficolin-2 are not considered as
orthologues molecules based on evolutionary neighbouring three
analyses [13,14], the present results show that these two molecules
might have similar properties. This suggest that ficolin-A knock-
out mice models might be highly relevant for human disease
model in general. However, one unresolved question that remains
to be addressed is the possible role of the ficolins in viral infections
and viral pathophysiology.
In conclusion, our results demonstrate that ficolin-A have
a broad binding profile towards both Gram-negative and Gram-
positive strains as well fungi. The binding properties towards
clinical relevant pathogens suggest that ficolin-A is an important
contributors to innate host defence against pathogens, but our
findings also indicate that the microbes may be able to utilize the
ficolins as virulence factors. Ficolin-A appears to share several of
the ficolin-2 binding properties although some differences in the
binding profile were observed. Ficolin-3 however, seems to have
a very restricted anti-microbial profile.
Materials and Methods
Maxisorp polystyrene microtiter plates were from NUNC
(Roskilde, Denmark). PBS-buffer (10 mM Na2HPO4, 1.47 mM
Figure 8. Binding of ficolin-A to E. coli using confocal laser scanning fluorescence microscopy. Ficolin-A (5 mg/ml) was incubated with
E. coli EC2 (A) or E. coli EC3 (B). The bacteria (4610
6 cells) were incubated with or without ficolin-A. Ficolin-A binding was only observed to E. coli EC2
and this binding was found on aggregated bacteria. The binding was detected with a monoclonal rat anti-mouse ficolin-A antibody.
doi:10.1371/journal.pone.0038196.g008
Ficolin-A and Microorganisms
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buffer (4 mM C8H11N2NaO3, 145 mM NaCl, 2.6 mM CaCl2,
2.1 mM MgCl2, pH=7.4) were from the hospital pharmacy
(RegionH Apoteket, Rigshospitalet, Copenhagen, Denmark).
Tween-20 was from Merck (Hohenbrunn, Germany). FITC-
conjugated swine anti-rabbit IgG was purchased from DAKO
(Glostrup, Denmark). Goat anti-rat IgG Alexa Fluor 488,
NuPAGE 3–8% Tris-acetate gels, Tris-acetate buffer, LDS
loading buffer and reducing agent were purchased from Invitrogen
(Taastrup, Denmark). HRP-conjugated streptavidin, HRP-cou-
pled anti-rabbit immunoglobulin, nitrocellulose membranes, ECL
hyperfilm and CNBr activated sepharose beads were from GE
Healthcare (Buckinghamshire, United Kingdom). SuperSignal
West Femto Maximum Sensitivity Substrate and Ready-to-use
TMB substrate were from Pierce Biotechnology (Rockford, IL,
USA). Chloramphenicol, tryptone, yeast extract, mannose agarose
beads, GlcNAc agarose beads and GlcNAc were from Sigma
(Brondby, Denmark). LPS Extraction Kit was from CHEMBIO
(Hertfordshire, UK). Sterile filter 0.2 mm was from VWR (Herlev,
Denmark). Sterile 40 mM cell strainer and the BD FACSCalibur
were from Becton Dickinson (Bilthoven, The Netherlands). The
monoclonal antibodies were produced in house; rat anti-mouse
ficolin-A (FCNA-K12), mouse anti-human ficolin-2 (FCN219),
mouse anti-human ficolin-3 (FCN334)). Polyclonal rabbit anti-
mouse ficolin-A (Japan) antibody was produced in house. In
selected experiments sera from ficolin-A and ficolin-B knock-out
mice were used (the construction and characterisation of these
mice will be reported elsewhere).
Recombinant Ficolins
Recombinant mouse ficolin-A was synthesized as previously
described for ficolin-2 and ficolin-3 [3,40]. Briefly, the FCNA gene
was amplified from mouse liver cDNA using the forward primer
59-ctagctcgacgcgagatgcagtggcctacgctgt-39 and the reverse primers
59-tccggaattccgttaagatgctcggattttcatctc-39. The constructs were
cloned into the expression vector pED.dC and transfected into
the Chinese hamster ovary (CHO) cell line CHO-DG44 (a kind
gift from professor Lawrence Chasin, Columbia University, New
York) using dhfr selection system. Subsequently, the recombinant
ficolin-A were purified from the cell supernatant on GlcNAc
agarose beads. Culture supernatants were centrifuged for 20 min
at 15,000 g to obtain cleared supernatants and then loaded onto
a column containing GlcNAc-agarose beads, which was been
equilibrated with Barb-T buffer (Barbital-buffer with 0.05%
Tween-20). The beads were washed with 100 times column
volume of Barb-T buffer and the ficolins were eluted with 0.25 M
GlcNAc in PBS buffer and dialyzed first into PBS containing
5 mM EDTA buffer and then pure PBS.
Coupling of acBSA and BSA to Sepharose Beads
A total of 0.1 g dry CNBr-activated Sepharose 4B beads were
allowed to swell in 1 mM HCl. After washing in 1 mM HCl, the
beads were incubated with 4 mg BSA or acetylated BSA for 4 h at
4uC in a buffer composed of 0.1 M NaHCO3 and 0.5 M NaCl
(pH 8.3). The beads were washed three times with the same buffer
and blocked with 1 M ethanolamine. The beads were washed in
0.1 M TRIS-HCl, 0.5 M NaCl (pH 8.5).
Bacteria
The following bacteria strains were examined in the assays:
Staphylococcus aureus (SA1–19: 8325-4, SH1000, COL, EMRSA,
SA564, 15981, USA300, Na34, m70, m124, m332, m137, Mu50,
M9, ST398, S84F9, UAMS-1, P1, ATCC25923), Escherichia coli
(EC1-3: O149, O157:H7, ATCC25922), Enterococcus faecalis (EF 1-
6: TX0052, OG1RF, HEF5, HEF5-scv1, HEF5-scv2, HEF5-
scv3), Listeria monocytogenes (LM1-3:10403S, ScottA, LO28), Salmo-
nella Typhimurium (ST1:4/74), Salmonella dublin (ST2:3246), Salmo-
nella gallinarium (ST3: G9), Pseudomonas aeruginosa (PS1-2:
ATCC27853, 53381), Streptococcus agalactiae (Group B streptococ-
cus) (SR1-6:33304, 33327, 33354, 54381, 33999, 33061), Staph-
ylococcus epidermidis (clinical isolate A33), and Klebsiella pneumoniae
(KB1:51046). All strains were grown in standard LB (Luria-
Bertani broth) medium.
Preparation of A. Fumigatus Conidia
The Aspergillus fumigatus strain was obtained from a clinical
isolate 6871 (University of Perugia, Italia). The A. fumigatus was
grown on Sabouraud dextrose agar supplemented with chloram-
phenicol by agar-streak for 4 days at 28uC. Abundant conidia were
obtained under these conditions. The conidia were harvested by
washing the slant culture with PBS containing 0.05% Tween-20
(PBS-T) and gently scraping the conidia from the mycelium with
sterile cotton-tipped applicators. The conidia were then allowed to
settle by gravity followed by filtration through sterile 40 mM cell
strainer to remove hyphal fragments and cell debris. After
extensive washing with PBS-T, the conidia were counted and
diluted to the desired concentrations. The A. fumigatus was heat-
inactivated at 121uC for 15 min prior to use.
Consumption Assay
Bacteria were incubated overnight at 37uC, shaking at 130 rmp
in 5 ml LB-medium. The overnight cultures were centrifuged at
9,000 g for 5 min and washed three times in PBS. The cell pellet
was resuspended in Barb-T buffer and the bacteria concentration
was estimated spectrophotometric at OD600nm, where absor-
bance value 1 corresponds to approximately 1610
9 cells/ml.
Bacteria (1610
8 cells) or fungus (1610
7 cells) were incubated
shaking for 2 h at 37uC with 0.4 mg/ml rficolin-A, rficolin-2 or
rficolin-3 in Barb-T buffer in a total volume of 500 ml. After
centrifugation (9,000 g, 5 min) the supernatant was transferred to
ficolin-A, ficolin-2 and ficolin-3 quantification assays described
below. The percentage of unbound ficolin was estimated by
dividing the signal from the sample containing the microorganisms
with the signal from the control sample without microorganisms.
Each test was repeated three times in duplicates. In some
experiments, ficolin-A wildtype or ficolin-A knock-out mice sera
(1:50) were incubated with bacteria and analysed as described
above. The bacteria pellet was washed three times in Barb-T
buffer and resuspended in SDS-PAGE loading buffer and
analyzed by western blotting.
Ficolin-A, Ficolin-2 and Ficolin-3 Quantification Assay
Microtiter plates were coated with 100 mlo f5mg/ml acBSA in
PBS-buffer overnight at 4uC. Plates were blocked for 1 h with
Barb-T and subsequently washed three times in Barb-T. Samples
were added to the wells and incubated for 2 h at 37uC. Ficolin-A
Figure 9. Binding of ficolin-A to E. faecalis (EF2) using confocal laser scanning fluorescence microscopy. The E. faecalis (4610
6 cells) was
incubated with ficolin-A (5 mg/ml) (A) or without ficolin-A (B). Ficolin-A binding was only observed to aggregated E. faecalis cells. 3D view of the
ficolin-A binding to aggregated bacteria (C). The binding was detected with a monoclonal rat anti-mouse ficolin-A antibody.
doi:10.1371/journal.pone.0038196.g009
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(Japan), ficolin-2 was detected with 0.5 mg/ml biotinylated mono-
clonal FCN219 and ficolin-3 was detected with 0.25 mg/ml
biotinylated monoclonal FCN334. Plates were incubated for 1 h at
37uC. After washing, HRP-coupled anti-rabbit immunoglobulin
(0.25 mg/ml) or HRP-conjugated streptavidin (1:6000) were added
for 1 h at 37uC. Plates were washed and developed for 10–15 min
with TMB substrate and stopped with 50 ml sulphuric acid/well.
The optical density was measured at 450 nm.
Dose Dependent Binding of Ficolins to Bacteria
Serial dilutions of overnight bacteria cultures (4-fold dilutions
starting from 1.5610
8 cells) were incubated for 2 h at 37uC,
shaking with 0.4 mg/ml rficolin-A, rficolin-2 or rficolin-3 in Barb-
T buffer in a total volume of 500 ml. After centrifugation (9,000 g,
5 min) the supernatants were transferred to ficolin-A, ficolin-2 and
ficolin-3 quantification assays described above.
Western Blotting
Bacteria pellet samples were diluted in SDS-buffer with
reducing agent and heated for 5 min at 90uC and applied to
SDS-PAGE using 3–8% Tris-acetate gels. The separated proteins
were subsequently blotted onto nitrocellulose membranes and the
membranes were blocked using a 5% skim milk solution in PBS-T
for 1 h at room temperature shaking. After a brief wash in PBS-T,
the membranes were incubated shaking for 1 h at room
temperature with 0.25 mg/ml polyclonal rabbit anti-mouse
ficolin-A (Japan) antibody. Following incubation, the membranes
were washed thoroughly in PBS-T and subsequently incubated
with 0.25 mg/ml anti-rabbit-HRP. Membranes were developed on
ECL hyperfilm with SuperSignal West Femto Maximum Sensi-
tivity Substrate.
Sterile Filtration and Heat Inactivation of Bacteria Growth
Medium
Overnight bacteria culture was centrifuged at 9,000 g for 5 min
and the growth medium were sterile filtrated using 0.2 mm filters
and heat inactivated at 96uC for 30 min.
LPS Purification
LPS was purified from 5 ml of overnight bacteria cultures
(S. typhimurium, P. aeruginosa and E.coli) using LPS Extraction Kit at
standard conditions. LPS was dissolved in 50 ml PBS.
LPS Assay
Purified LPS from S. typhimurium, P. aeruginosa and E.coli were
coated in polystyrene plates in 2-fold dilutions starting from 5 ml/
well. Plates were blocked for 1 h with Barb-T and were
subsequently washed twice in Barb-T. Ficolin-B knock-out serum
diluted 1:10 in Barb-T buffer was added to the wells and incubated
for 2 h at 37uC. Ficolin-A was detected with 0.25 mg/ml
polyclonal rabbit anti-mouse ficolin-A (Japan) antibody for 1 h
at 37uC. After washing, HRP-coupled anti-rabbit immunoglobulin
(0.25 mg/ml) was added for 1 h at 37uC. Plates were washed and
developed for 10–15 min with TMB substrate. Addition of 50 ml/
well sulphuric acid terminated the enzymatic reaction. The optical
density was measured at 450 nm.
Flow Cytometry
A. fumigatus conidia (1.4610
6 cells) were washed and resus-
pended in TBS-Mg
2+ (10 mM Tris/150 mM NaCl/1.5 mM
CaCl2/1 mM MgCl2, pH 7.4) buffer containing 1% heat-
inactivated FCS (TBS-Mg
2+/HI-FCS), followed by incubation
with elevated concentration of mouse ficolin-A at 37uC for 1 h. All
reaction volumes were 100 ml and A. fumigatus were washed after
each step in cold TBS-Mg
2+/HI-FCS. Bound proteins were
detected with polyclonal rabbit anti-mouse ficolin-A (Japan)
antibody by incubation at 4uC for 30 min, followed by 15 min
of incubation at 4uC with FITC-conjugated anti-rabbit IgG.
Finally, the A. fumigatus were washed and resuspended in 200 mlo f
cold TBS-Mg
2+/HI-FCS. Flow cytometry was performed at the
BD FACSCalibur and data was analyzed by BD CellQuest Pro
software. In some experiments, A. fumigatus (1.4610
6 cells) were
incubated with mouse ficolin-A (30 mg/ml) in TBS-Mg
2+/HI-FCS
in the presence of GlcNAc (0.1 M) and mannose (0.1 M),
respectively. Bound ficolin-A was detected as depicted above. As
a control A. fumigatus was incubated in the absence of mouse
ficolin-A.
Confocal Laser Scanning Fluorescence Microscopy
Ficolin-A (5 mg/ml) was incubated with 4610
6 microbial cells in
Barb-T buffer in a total volume of 200 ml for 1 h at 37uC. After
centrifugation (9,000 g, 5 min) the cell pellet was incubated with
an in house produced monoclonal rat anti-mouse ficolin-A
antibody (FCNA-K12) for 1 h at 37uC. After centrifugation
(9,000 g, 5 min) the cell pellet was washed and incubated with
anti-rat IgG Alexa Fluor 488 for 1 h at 37uC. The cells were
washed and the samples were examined using a Zeiss LSM 710
confocal laser scanning microscope (CLSM) equipped with an
Argon laser for excitation of the Alexa Fluor 488. The images were
further processed using the IMARIS software package (Bitplane
AG).
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